XSXiaomei Sun

Xiaomei Sun

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Xiaomei Sun has a total of 26 co-authors. Here are the top co-authors by number of shared publications:

  • Shuting Lan

    Clinical Medicine Research Center, Affiliated Hospital of Inner Mongolia Medical University, Hohhot, Inner Mongolia, People’s Republic of China

    5 shared publications
  • Gang Liu

    Clinical Medicine Research Center, Affiliated Hospital of Inner Mongolia Medical University, No. 1 Tongdao North Street, Hohhot, Inner Mongolia 010050, China

    4 shared publications
  • Rongrong Zhang

    Clinical Research Center, Affiliated Hospital of Inner Mongolia Medical University, Hohhot, China

    2 shared publications
  • Wenqi Zhang

    Southeast University 1 Department of Microbiology and Immunology, Jiangsu Provincial Key Laboratory of Critical Care Medicine, Zhongda Hospital, School of Medicine Nanjing, China

    2 shared publications
  • Bi-Chao Wen

    Key Laboratory of Medical Cell Biology, Department of Achievement Transformation, Affiliated Hospital of Inner Mongolia Medical University, Hohhot 010050, China

    1 shared publication
  • Hua Du

    Department of Pathology, Affiliated Hospital of Inner Mongolia Medical University, Hohhot, Inner Mongolia, People’s Republic of China

    1 shared publication

Latest Publications

  • Open Access

    Anti-cancer effect of palmitic acid against the endometrial cancer progression via inducing ferroptosis

    by Shuting Lan, Xiaomei Sun, Qiyuan Bo, Suriguga Wang, Yifan Qin, Jianying Mao


  • Open Access

    Selenium nanoparticles mitigate Cyclophosphamide-Induced premature ovarian failures in mice by activating PI3K/AKT signaling pathway and inhibiting ferroptosis

    by Gang Liu, Lina Dai, Rongrong Zhang, Mengxuan Jia, Shuting Lan, Xiaomei Sun, Zhikang Wang, Yanfeng Dai, Shuwei Yang

    The therapeutic role and mechanisms of selenium nanoparticles (SeNPs) in cyclophosphamide (CTX)-induced premature ovarian failure (POF) remain unclear. In the present study, female mice were treated with CTX to induce POF, followed by SeNPs administration for 14 consecutive days. Ovarian weight, index, and serum hormone levels were measured to assess ovarian function. Histological examination of ovarian tissues was conducted to examine morphological changes, folliculogenesis, DNA damage, and apoptosis. Transcriptomic analysis was performed to identify the underlying molecular mechanisms, with in vitro studies on ovarian granulosa cells employed to validate the findings. The results confirmed that SeNPs administration effectively restored ovarian morphology and function, increasing the number of developing follicles and decreasing the number of atretic follicles. Notably, SeNPs significantly reversed CTX-induced hormonal disturbances: estradiol (E2) levels increased from 186.24 ± 14.72 pM (CTX group) to 258.28 ± 7.53 pM (SeNPs group); follicle-stimulating hormone (FSH) decreased from 20.74 ± 1.13 IU/L to 15.96 ± 1.07 IU/L; luteinizing hormone (LH) declined from 24.88 ± 1.16 ng/mL to 18.04 ± 1.60 ng/mL; and anti-Müllerian hormone (AMH) rose from 164.02 ± 8.57 pg/mL to 230.30 ± 12.01 pg/mL. Moreover, SeNPs attenuated CTX-induced DNA damage and apoptosis of granulosa cells. Transcriptomic analysis identified that SeNPs exert their protective effects against CTX-induced POF by activating the PI3K/AKT signaling pathway and inhibiting ferroptosis, as evidenced by the expression patterns of PI3K/AKT signaling pathway-related proteins and ferroptosis-related markers in granulosa cells. In conclusion, SeNPs effectively protect against CTX-induced POF by enhancing ovarian function, promoting folliculogenesis, and inhibiting DNA damage and apoptosis of granulosa cells. These protective effects are mediated through the activation of the PI3K/AKT signaling pathway and suppression of ferroptosis. Our findings suggest that SeNPs hold promise as a promising therapeutic strategy for ovarian dysfunction, particularly in the context of chemotherapy-induced POF.


  • Open Access

    Synthesis of Zinc Oxide-Doped Carbon Dots for Treatment of Triple-Negative Breast Cancer

    by Mengqi Wang, Shuting Lan, Mingjun Song, Rongrong Zhang, Wenqi Zhang, Xiaomei Sun, Gang Liu

    Introduction: The anti-cancer properties of zinc oxide-doped carbon dots (CDs/ZnO) in inhibiting triple-negative breast cancer (TNBC) progression merit more investigation. Methods: With citric acid as the carbon source, urea applied as the nitrogen source, and zinc oxide (ZnO) used as a reactive dopant, CDs/ZnO were synthesized by microwave heating in the current study, followed by the characterization and biocompatibility assessments. Subsequently, the anti-cancer capabilities of CDs/ZnO against TNBC progression were evaluated by various biochemical and molecular techniques, including viability, proliferation, migration, invasion, adhesion, clonogenicity, cell cycle distribution, apoptosis, redox homeostasis, metabolome, and transcriptome assays of MDA-MB-231 cells. Additionally, the in vivo anti-cancer potentials of CDs/ZnO against TNBC progression were analyzed using TNBC xenograft mouse models. Results: The biocompatibility of CDs/ZnO was supported by the non-significant changes in the pathological and physiological parameters in the CDs/ZnO treated mice, alongside a non-cytotoxic effect of CDs/ZnO on the proliferation of normal cells. Notably, the CDs/ZnO treatments effectively decreased the viability, proliferation, migration, invasion, adhesion, and clonogenicity of MDA-MB-231 cells. Furthermore, the CDs/ZnO treatments induced cell cycle arrest, apoptosis, redox imbalance, metabolome disturbances, and transcriptomic alterations of MDA-MB-231 cells by regulating the MAPK signaling pathway. Additionally, the CDs/ZnO treatments markedly suppressed the in vivo tumor growth in the TNBC xenograft mouse models. Conclusion: In this study, we synthesized CDs/ZnO via microwave heating, using citric acid as the carbon source, urea as the nitrogen source, and ZnO as a reactive dopant. We confirmed the biosafety and potent anti-cancer efficacy of CDs/ZnO in inhibiting TNBC progression by disrupting malignant cell behaviors through modulation of the MAPK signaling pathway.


  • Regulation of Fuzheng Huayu capsule on inhibiting the fibrosis-associated hepatocellular carcinogenesis

    by Wen-Qi Zhang, Jia-Xin Sun, Shu-Ting Lan, Xiao-Mei Sun, Yi-Jing Guo, Bi-Chao Wen, Jie Chen, Gang Liu

    In the current study, bioinformatics analysis of the hepatocellular carcinoma (HCC) dataset was conducted with the hepatoprotective effect of the Fuzheng Huayu (FZHY) capsule against the diethylnitrosamine-induced HCC progression analyzed. Eight cell clusters were defined and tanshinone IIA, arachidonic acid, and quercetin, compounds of the FZHY capsule, inhibit HCC progression-related fibrosis by regulating the expression of PLAU and IGFBP3. Combined with the ameliorative effect of the FZHY capsule against liver dysfunctions and expression of PLAU and IGFBP3, our study confirmed the effect of the FZHY capsule on inhibiting the fibrosis-associated HCC progression via regulating the expression of PLAU and IGFBP3.


  • Open Access

    Anti-Cancer Potency of Copper-Doped Carbon Quantum Dots Against Breast Cancer Progression

    by Mengqi Wang, Shuting Lan, Wenqi Zhang, Qin Jin, Hua Du, Xiaomei Sun, Lijun He, Xiangyun Meng, Liya Su, Gang Liu

    Introduction: The anti-cancer potency of copper-doped carbon quantum dots (Cu-CDs) against breast cancer progression needs more detailed investigations. Methods: With urea and ethylene glycol applied as carbon sources and copper sulfate used as a reactive dopant, Cu-CDs were synthesized in the current study by a one-step hydrothermal synthesis method, followed by the characterization and biocompatibility evaluations of Cu-CDs. Subsequently, the anti-cancer potency of Cu-CDs against breast cancer progression was confirmed by these biochemical, molecular, and transcriptomic assessments, including viability, proliferation, migration, invasion, adhesion, clonogenicity, cell cycle distribution, apoptosis, redox homeostasis, and transcriptomic assays of MDA-MB-231 cells. Results: The biocompatibility of Cu-CDs was confirmed based on the non-significant changes in the pathological and physiological parameters in the Cu-CDs treated mice, as well as the noncytotoxic effect of Cu-CDs on normal cells. Moreover, the Cu-CDs treatments not only decreased the viability, proliferation, migration, invasion, adhesion, and clonogenicity of MDA-MB-231 cells but also induced the redox imbalance, cell cycle arrest, and apoptosis of MDA-MB-231 cells via ameliorating the mitochondrial dysfunctions and regulating the MAPK signaling pathway. Conclusion: Our findings confirmed the biosafety and excellent anti-cancer potency of Cu-CDs against breast cancer progression by tapping into mechanisms that disrupt malignant behaviors and oxidative homeostasis of breast cancer cells.